For the latest updates on GSK’s response to COVID-19, please
click here.
Our Purpose:
At Haleon, we have a clear purpose: to deliver better everyday health with humanity. As part of this commitment, we recognise the valuable role that Supported Studies (Investigator-Sponsored Studies (ISS) and Supported Collaborative Studies (SCS)) play in fulfilling this purpose.
The Supported Studies Programme:
Supported Studies are research conducted by an external Sponsor with Haleon’s support. There are two different ways Haleon can provide support:
-
Investigator Sponsored Studies are entirely designed and managed by an external Sponsor. Haleon can support in the form of funding and/or product (including Haleon products, placebo, or other medicinal products necessary for the research). These studies are also known as Investigator-Initiated Studies, Investigator-Initiated-Trials, Investigator Initiated Research or Investigator Sponsored Research.
-
Supported Collaborative Studies are conducted by an external Sponsor, with Haleon contributing to study design and deliverables, in addition to the provision of funds and/or products.
In both circumstances the Sponsor of the research is accountable for all aspects of the study as well as for complying with all applicable ethical, regulatory and legal requirements.
Haleon reviews proposals received at set points throughout the year. Haleon is committed to responding to your proposal within eight weeks from the closing date of the relevant submission period.
Disease Area
|
Cycle
|
Submission period opens
|
Submission period close
|
Proposal of Interest communicated
|
First draft of protocol requested
|
Additional Information
|
Consumer Health
|
Cycle 1
|
01 Jan 2024
|
31 Mar 2024
|
26 May 2024
|
N/A
|
|
Consumer Health
|
Cycle 2
|
01 April 2024
|
30 Jun 2024
|
25 Aug 2024
|
N/A
|
|
Consumer Health
|
Cycle 3
|
01 Jul 2024
|
30 Sep 2024
|
25 Nov 2024
|
N/A
|
|
Consumer Health
|
Cycle 4
|
01 Oct 2024
|
31 Dec 2024
|
25 Feb 2025
|
N/A
|
|
The below areas are of particular interest to the review committee. This was last updated in April 2024.
Oral Health
Dental Plaque at the Gingival Margin
-
Characteristics, interaction among organisms and local immune response, consequences over defined periods of time, influencing factors.
Gingival Inflammation
-
Gingivae in health and disease: characterisation of extent of inflammation, markers, impact on rest of periodontium and oral health, longitudinal sequalae.
Enamel Health
-
Teeth are subject to numerous challenges throughout the day from dietary sugars, acids and bacteria. Despite the use of fluoridated toothpaste and mouthwash, all these factors have contributed to a significant rise in the number of fillings, enamel wear and sensitivity. Therefore, we are seeking solutions that would protect tooth enamel from these challenges and/or repair the damage that has been caused, and/or drive further understanding of the conditions.
Dentine Hypersensitivity
-
Dentin hypersensitivity is a relatively common condition; it is one of the most commonly encountered clinical problems in dentistry. Dentine hypersensitivity is characterized by tooth pain in response to stimuli such as hot and cold food and can have a marked impact the enjoyment of daily activities and quality of life. However, the condition is manageable, and we continue to seek to develop products that help prevent the pain of dentine hypersensitivity, and explore new understandings on the condition, including impacts on quality of life, objective measures of pain and physiological parameters.
Toothbrushes
-
Epidemiological insights around toothbrushing
-
Role of toothbrushes in aetiology of dentine hypersensitivity
-
Techniques to clinically measure cervical /gingival abrasion
The Burden of Tooth Loss
-
Implications and consequences: Function, Oral Health, Quality of Life
-
Role of dental professionals in managing change/transition for patients facing/ living with tooth loss
Care of Appliances as Part of Daily Oral Hygiene Routine
-
Oral hygiene needs of partially dentate patients
-
Evidence base for prevention of oral diseases in partially dentate populations
Fit and Performance of Removable Dentures
-
Masticatory function
-
Oral health
-
Patients perceived needs
Oral and Systemic Health Linkage
-
Bi-directional linkage of oral health and systemic health conditions (e.g., diabetes, rheumatoid arthritis)
-
Future technologies/diagnostic tools to assess oral health and systemic health linkage
-
Role of the dental professionals in holistic whole-body wellbeing
Oral Microbiome
-
Role of oral bacteria (composition and function) in health and disease.
Pain relief
Haleon scientists research and develop self-treatment options to manage a range of mild to moderate pain types. The goal of Haleon's research in pain is to provide treatments and interventions that significantly improve the lives of patients living with a range of painful conditions.
We welcome research proposals especially those that evaluate:
-
The use of non-prescription pain relievers in mild to moderate pain conditions
-
Use of oral and topically applied natural products for pain
-
Combination treatments in the management of pain
Respiratory
-
Upper respiratory tract infections
-
Allergic and non-allergic rhinitis
-
Air pollution
Wellness
Wellness category is interested in receiving and reviewing proposals related to research in dietary supplements (DS):
-
Healthy Ageing
-
Immunity and inflammation
-
Cardiovascular and metabolic related issues
-
Brain health
-
Real World Data research methods on DS product outcome and efficacy
-
Immunity and nutrition
-
Energy-yielding cellular metabolism
-
Inflammation and nutrition
-
Self-care and food supplement efficacy
Digital & Devices
Digital health can be broadly defined as the use of digital technology, data and the internet to improve either access, efficiency, the consumer/patient experience, or outcomes (or a combination of these) in healthcare.
Haleon welcomes research proposals in the field of digital health. We have a broad scope of interest for such proposals and are keen to hear of any which may include studies that:
-
Assess the use of apps and other digital technologies to improve health outcomes or the patient/consumer experience in any of the therapy areas in which Haleon has a publicly declared interest
-
Address the areas of resilience, pain, anxiety, smoking cessation (and other forms of addiction), health-related behaviour change, weight management, wellness, mental health, oral health, allergy, infectious diseases and cold & flu
-
Assess the utility of digital therapeutics or platforms in areas of interest, where the therapeutic/platform may be a standalone intervention or an adjunct to a conventional medicine/medical device
-
Investigate the potential health benefits of wearable technologies
-
Investigate innovative ways to collect real world evidence on healthcare interventions
-
Investigate innovative ways to monitor/assess the safety of healthcare interventions
-
Investigate consumer, patient, HCP, regulator or policymaker attitudes to, and acceptance of, digital health interventions
-
Investigate how digital health interventions may reduce the burden on healthcare systems
Submit your proposal
Landmark GEMINI studies meet primary endpoint
Today, we announced positive headline results from ViiV Healthcare's landmark phase III GEMINI study programme. This continues our game-changing efforts to provide patients with HIV with the option to take two medicines instead of three, while still controlling the virus.
The 48-week primary endpoint results from the GEMINI studies, which used a two-drug regimen of dolutegravir and lamivudine, show that adults who had never received treatment for HIV could get a similar level of efficacy from taking the 2DR as they could from taking a three-drug regimen.
"The Gemini studies show that 2DRs could be an option for treatment naïve patients and can support a broad range of patients living with HIV around the world." said John Pottage MD, Chief Scientific and Medical Officer of ViiV Healthcare.
"The timely delivery of these important outcomes is the result of tremendous hard work and collaboration between ViiV and the GSK Team," said Kathy Rouan, SVP and Head of Projects, Clinical Platforms and Sciences (PCPS). "I want to extend my personal thanks to all of you who have contributed to this outcome; for your focus on these patients and the impact that your diligence and high performance will achieve."
"We believe these data represent an important step in the journey to redefine HIV treatment, confirming the fundamental principle that no one should have to take more medicines than they need." added Deborah Waterhouse, CEO, ViiV Healthcare.
Full results from the GEMINI studies will be presented at upcoming scientific conference. ViiV Healthcare will now plan for regulatory submissions for the two-drug regimen of dolutegravir and lamivudine later this year.
Read more